B-cell-directed therapy: Which B cells should be targeted and how?

Immunotherapy

Volumn 4, Issue 5, 2012, Pages 455-457

  Yamamura, Takashi ^a   Miyake, Sachiko ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

anti CD19; anti CD20; neuromyelitis optica; plasmablast; rituximab

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CORTICOSTEROID; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; NATALIZUMAB; RITUXIMAB; TOCILIZUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CORTICOSTEROID THERAPY; DRUG EFFICACY; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; MEMORY CELL; MONOCYTE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD20; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; NEUROMYELITIS OPTICA; PRECURSOR CELLS, B-LYMPHOID; RECEPTORS, INTERLEUKIN-6;

EID: 84861701837     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.35     Document Type: Review

References (19)

1. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 54(9), 2793-2806 (2006).
2. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-Associated vasculitis. N. Engl. J. Med. 363(3), 221-232 (2010).
3. Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimeric anti CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am. J. Hematol. 78(4), 275-280 (2005).
4. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358(7), 676-688 (2008).
5. Pellkofer HL, Krumbholz M, Berthele A et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15), 1310-1315 (2011).
6. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE. Are autoantibodies the targets of B-cell-directed therapy? Nat. Rev. Rheumatol. 7(9), 551-556 (2011).
7. Tedder TF. CD19: A promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 572-577 (2009).
8. Jarius S, Paul F, Franciotta D et al. Mechanisms of disease: Aquaporin 4 antibodies in neuromyelitis optica. Nat. Clin. Prac. Neurol. 4(4), 202-214 (2008).
9. Lennon VA, Wingerchuk DM, Kryzer TJ et al. Serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364(9451), 2106-2112 (2004).
10. Okamoto T, Ogawa M, Lin Y et al. Review: Treatment of neuromyelitis optica: Current debate. Ther. Adv. Neurol. Disord. 1(1), 43-52 (2008).
11. Kleiter I, Hellwig K, Berthele A et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch. Neurol. 69(2), 239-245 (2012).
12. Osoegawa M, Kira J, Fukazawa T et al.; Research Committee of Neuroimmunological Diseases. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: Nationwide survey results over 30 years. Mult. Scler. 15(2), 159-173 (2009).
13. Wilk E, Witte T, Marquardt N et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 60(12), 3563-3571 (2009).
14. Stasi R, Del PG, Stipa F et al. Response to B-cell depletion therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8), 2924-2930 (2007).
15. Lehmann-Horn K, Shleich E, Hertzenberg D et al. Anti CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J. Neuroinflammation 8, 146 (2011).
16. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL 10-competent B-cell subset in humans that parallels mouse regulatory B cells. Blood 117(2), 530-541 (2011).
17. Chihara N, Aranami T, Sato W et al. Interleukin 6 signaling promotes anti-Aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl Acad. Sci. USA 108(9), 3701-3706 (2011).
18. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin 6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219 (2012).
19. Owczarczyk K, Lal P, Abbas AR et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci. Transl Med. 3(101), 101ra92 (2011).